Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
about
Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease.Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation typesValue of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function
P2860
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Lucerastat, an Iminosugar for ...... Disease on Enzyme Replacement.
@en
Lucerastat, an Iminosugar for ...... Disease on Enzyme Replacement.
@nl
type
label
Lucerastat, an Iminosugar for ...... Disease on Enzyme Replacement.
@en
Lucerastat, an Iminosugar for ...... Disease on Enzyme Replacement.
@nl
prefLabel
Lucerastat, an Iminosugar for ...... Disease on Enzyme Replacement.
@en
Lucerastat, an Iminosugar for ...... Disease on Enzyme Replacement.
@nl
P2093
P2860
P356
P1476
Lucerastat, an Iminosugar for ...... Disease on Enzyme Replacement.
@en
P2093
Christian Zwingelstein
Christoph Wanner
Daniel Oder
Jasper Dingemanse
Nicolas Guérard
Olivier Morand
Richard W D Welford
P2860
P304
P356
10.1002/CPT.790
P407
P577
2017-07-12T00:00:00Z